Levitee Labs Inc.

CSE: LVT

Company Overview

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

The company's current portfolio of assets includes Sporeo and MONKE Nutraceuticals. Sporeo manufacturers the first commercial grade offering of spawn and substrate and has mass distribution agreements in place with leading global distributors. Sporeo is currently developing an ecommerce platform that will be a centralized portal for all mushroom cultivation needs. MONKE specializes in the development and distribution of premium functional mushroom supplements. This adaptogenic product line was formulated to enhance consumers' wellbeing. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.15

Diluted EPS (ttm)

Management Team

Mr. David Bentil
CEO & Director

Mr. Marc Momeni
Exec. VP & Co-Founder

Mr. Pouya Farmand
Co-Founder

Mr. Mackenzie Osborne C.F.A.
Head of M&A, Co-Founder and Director

Maigul Wickham CPA
Chief Financial Officer

Mr. Kelly Abbott
COO & Director

Dr. Fady Hannah-Shmouni FRCPC, M.D.
Chief Medical & Scientific Officer and Pres of Clinics

Olivia Belcher-Coward
Marketing & Communications Mang.

Mr. Azim Qazi M.B.A.
Head of Ecommerce & Consumer Packaged Goods

Dr. Mohammed H. Mosli FRCPC, M.D.
Chief People Officer of Levitee Clinics & Pharmacies and Member of Medical Advisory Board

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
37%